01093 CSPC PHARMA
- 6.220
- +0.170+2.81%
CSPC PHARMA News
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
CSPC PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL
CSPC PHARMA: CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL
CSPC PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - INDICATION FOR ACUTE ISCHEMIC STROKE OF MINGFULE (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) OBTAINS MARKETING APPROVAL
CSPC PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
CSPC PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023
CSPC PHARMA: ELECTIONS OF MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS
CSPC PHARMA: FIRST LETTER AND REPLY FORM - ELECTIONS AS TO MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR IRINOTECAN LIPOSOME INJECTION TO U.S. FDA
Analysis
Price Target
No Data
